Jeremy Di Domizio

Jeremy Di Domizio

Auto-generated profile, based on publicly available information

Jeremy Di Domizio

Department of Dermatology Lausanne University Hospital CHUV and University of Lausanne Lausanne Switzerland

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 2022 in Nature
Verified
Journal Article
Open access
PDF file
JDJeremy Di Domizio
Jeremy Di Domizio
MGMuhammet F. Gulen
Muhammet F. Gulen
FSFanny Saidoune
Fanny Saidoune
VTVivek Vijay Thacker
Vivek Vijay Thacker
AYAhmad Yatim
Ahmad Yatim
AAAndrea Ablasser
Andrea Ablasser
COVID-19, which is caused by infection with SARS-CoV-2, is characterized by lung pathology and extrapulmonary complications1,2. Type I interferons (IFNs) have an essential role in the pathogenesis of COVID-19 (refs 3–5). Although rapid induction of type I IFNs limits virus propagation, a sustained increase in the levels of type I IFNs in the late phase of the infection is associated with aberrant inflammation and poor clinical outcome5–17. Here we show that the cyclic GMP-AMP synthase (cGAS)–stimulator of interferon genes (STING) pathway, which controls immunity to cytosolic DNA, is a critical driver of aberrant type I IFN responses in COVID-19 (ref. 18). Profiling COVID-19 skin manifestations, we uncover a STING-dependent type I IFN signature that is primarily mediated by macrophages adjacent to areas of endothelial cell damage. Moreover, cGAS–STING activity was detected in lung samples from patients with COVID-19 with prominent tissue destruction, and was associated with type I IFN responses. A lung-on-chip model revealed that, in addition to macrophages, infection with SARS-CoV-2 activates cGAS–STING signalling in endothelial cells through mitochondrial DNA release, which leads to cell death and type I IFN production. In mice, pharmacological inhibition of STING reduces severe lung inflammation induced by SARS-CoV-2 and improves disease outcome. Collectively, our study establishes a mechanistic basis of pathological type I IFN responses in COVID-19 and reveals a principle for the development of host-directed therapeutics.

12 June 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
FMFeiyang Ma
Feiyang Ma
OPOlesya Plazyo
Olesya Plazyo
ABAllison C. Billi
Allison C. Billi
LTLam C. Tsoi
Lam C. Tsoi
XXXianying Xing
Xianying Xing
JGJohann Gudjonsson
Johann Gudjonsson
The immunopathogenesis of psoriasis, a common chronic inflammatory disease of the skin, is incompletely understood. Here we demonstrate, using a combination of single cell and spatial RNA sequencing, IL-36 dependent amplification of IL-17A and TNF inflammatory responses in the absence of neutrophil proteases, which primarily occur within the supraspinous layer of the psoriatic epidermis. We further show that a subset of SFRP2+ fibroblasts in psoriasis contribute to amplification of the immune network through transition to a pro-inflammatory state. The SFRP2+ fibroblast communication network involves production of CCL13, CCL19 and CXCL12, connected by ligand-receptor interactions to other spatially proximate cell types: CCR2+ myeloid cells, CCR7+LAMP3+ dendritic cells, and CXCR4 expressed on both CD8+ Tc17 cells and keratinocytes, respectively. The SFRP2+ fibroblasts also express cathepsin S, further amplifying inflammatory responses by activating IL-36G in keratinocytes. These data provide an in-depth view of psoriasis pathogenesis, which expands our understanding of the critical cellular participants to include inflammatory fibroblasts and their cellular interactions.

2 January 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
CCCurdin Conrad
Curdin Conrad
JDJeremy Di Domizio
Jeremy Di Domizio
AMAlessio Mylonas
Alessio Mylonas
CBCyrine Belkhodja
Cyrine Belkhodja
ODOlivier Demaria
Olivier Demaria
MGMichel Gilliet
Michel Gilliet
Although anti-tumor necrosis factor (TNF) agents are highly effective in the treatment of psoriasis, 2–5% of treated patients develop psoriasis-like skin lesions called paradoxical psoriasis. The pathogenesis of this side effect and its distinction from classical psoriasis remain unknown. Here we show that skin lesions from patients with paradoxical psoriasis are characterized by a selective overexpression of type I interferons, dermal accumulation of plasmacytoid dendritic cells (pDC), and reduced T-cell numbers, when compared to classical psoriasis. Anti-TNF treatment prolongs type I interferon production by pDCs through inhibition of their maturation. The resulting type I interferon overexpression is responsible for the skin phenotype of paradoxical psoriasis, which, unlike classical psoriasis, is independent of T cells. These findings indicate that paradoxical psoriasis represents an ongoing overactive innate inflammatory process, driven by pDC-derived type I interferon that does not lead to T-cell autoimmunity.

13 July 2020 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
JDJeremy Di Domizio
Jeremy Di Domizio
CBCyrine Belkhodja
Cyrine Belkhodja
PCPauline Chenuet
Pauline Chenuet
AFAnissa Fries
Anissa Fries
TMTimothy Murray
Timothy Murray
MGMichel Gilliet
Michel Gilliet

4 December 2017 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
SASolana G. Alculumbre
Solana G. Alculumbre
VSViolaine Saint-André
Violaine Saint-André
JDJeremy Di Domizio
Jeremy Di Domizio
PVPablo Vargas
Pablo Vargas
PSPhilemon Sirven
Philemon Sirven
VSVassili Soumelis
Vassili Soumelis

15 May 2018 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
NGNicolas Gestermann
Nicolas Gestermann
JDJeremy Di Domizio
Jeremy Di Domizio
Roberto LandeRoberto Lande
Roberto Lande
ODOlivier Demaria
Olivier Demaria
Loredana FrascaLoredana Frasca
Loredana Frasca
MGMichel Gilliet
Michel Gilliet
Lupus erythematosus (LE) patients develop autoantibodies that form circulating immune complexes (ICs) with extracellular self-nucleic acids. These ICs are deposited into peripheral tissues, where they trigger detrimental organ inflammation. Recent evidence suggests that ICs contain LL37–DNA complexes derived from neutrophil extracellular traps (NETs) and that LE patients develop pathogenic autoantibodies against these structures, including Abs to LL37. However, the mechanism that leads to the generation of these Abs is unknown. In this study, we show that NETs directly trigger Ab production by human memory B cells. This occurs via LL37–DNA complexes present in NETs, which have the unique ability to gain access to endosomal compartments of B cells and to trigger TLR9 activation. In LE patients, NET-derived LL37–DNA complexes trigger polyclonal B cell activation via TLR9, but also specifically expand self-reactive memory B cells producing anti-LL37 Abs in an Ag-dependent manner. These findings suggest a unique link between neutrophils and B cells in which NETs trigger a concerted activation of TLR9 and BCR leading to anti-NET autoantibody production in lupus.